Docetaxel‐induced interstitial lung disease among patients with breast cancer: a case series and review of literature

Hettiarachchi, Sanjeewa Malinda; Thilakaratne, Dilanka; Dharmasena, Dawpadee; Rathnapala, Amila; Abeysinghe, Prasad; Perera, Eshanth

doi:10.1002/rcr2.802

Cited by 10 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common form is interstitial pneumonitis which can develop within days to weeks following receiving docetaxel and paclitaxel or it can arise in the later course of the therapy (4). The largest case series described 18 cases of interstitial pneumonitis which developed following docetaxel show bilateral reticular or nodular patterns or ground glass opacities predominantly in the periphery of upper lungs (6). Doxorubicin can very rarely cause OP, but direct co-relation is not proven (1).…”

Section: Discussionmentioning

confidence: 99%

“…OP pattern in docetaxel-induced pneumotoxicity is yet to be defined in terms of the time of onset and major contributing risk factors. Based on current literature, patients with underlying chronic lung disease, lung malignancy and those who have had radiotherapy are known to be at high risk of developing lung injury (6). Paclitaxel is more pneumotoxic than docetaxel.…”

Section: Hrct Images On Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Docetaxel- induced organising pneumonia in a patient with advanced breast cancer: case report

Liyanage

Perera

Ranaweera

2023

Asian J. Internal Med.

View full text Add to dashboard Cite

Pulmonary toxicity is a rare complication of taxanes, which are used in chemotherapy regimes in advanced breast carcinoma. We report a case of a 47-year-old woman with locally advanced breast carcinoma who developed organizing pneumonia following docetaxel based neoadjuvant chemotherapy. Following exclusion of infective causes, she was treated with prednisolone, resulting in a remarkable clinical and radiological resolution on high resolution computed tomography. Early identification and judicious steroid therapy can provide excellent outcomes in patients with docetaxel induced interstitial lung disease despite reported high morbidity and mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Hrct Images On Diagnosismentioning

confidence: 99%

Docetaxel- induced organising pneumonia in a patient with advanced breast cancer: case report

Liyanage

Perera

Ranaweera

2023

Asian J. Internal Med.

View full text Add to dashboard Cite

show abstract

“…In a study conducted by Hettiarachchi et al reported that patients with prior lung anomaly were shown to have increased risk of ILD. 4 The incubation period between the administration of the drug and the onset of lung injury is mostly unpredictable but most studies have a mean time gap of about 15±3 days. In a study by Manuprasad et al conducted on 477 patients, the median time gap from administration of last dose to onset of symptoms and median hospital stay were 16 days (8-28 days) and 8.5 days (7-18 days) respectively.…”

Section: Discussionmentioning

confidence: 99%

Docetaxel induced subacute interstitial lung disease in a patient with prostate cancer

et al. 2022

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a collective term for a group of disorders that result in inflammation and scarring of the lung interstitium. Although majority of the cases of ILD are idiopathic, some of the etiologies can range from viral infections; connective tissue disorders or drug injury. Docetaxel is an anticancer agent of taxoid family that can rarely cause pulmonary toxicity. It can be occasionally used for the management of advanced prostate cancer. The adverse effects of the medication are mediated by type I and type IV hypersensitivity reactions. Here, we reported a case of 68-year-old man with advanced prostate cancer who completed six cycles of chemotherapy with docetaxel and presented with shortness of breath, low-grade fever and cough two weeks after completion of scheduled regimen. Clinical examination revealed diffuse wheeze and decreased air entryon auscultation, oxygen desaturation and an ulcerative lesion on the left forearm. All his routine serum, sputum and autoimmune profile were inconclusive. The inflammatory markers (CRP, ESR) were raised but procalcitonin was in normal range. Pulmonary function tests were indicative of restrictive lung disease. Digital chest X-ray revealed diffuse opacification with prominent bronchovascular markings and HRCT of thorax reported bilateral scattered honeycomb appearance, subpleural opacities, centrilobular nodules with air trapping. Docetaxel induced interstitial lung disease (DILD) was diagnosed and the patient was advised with high dose systemic and inhalational steroids along with external oxygen support. Rapid clinical improvement was seen and the patient was eventually discharged with tapering doses of oral steroids, physiotherapy and close follow-up.

show abstract

“…Hormone combination therapy analysed in this study included either a GnRH agonist or GnRH antagonist in combination with an ARA or an ASI, or a GnRH agonist or GnRH antagonist in combination with an ARA and an ASI. We then chose taxanes, including paclitaxel, docetaxel and cabazitaxel, as a positive control because they are associated with ILD and widely used for the treatment of prostate cancer 10,20,21 …”

Section: Methodsmentioning

confidence: 99%

“…We then chose taxanes, including paclitaxel, docetaxel and cabazitaxel, as a positive control because they are associated with ILD and widely used for the treatment of prostate cancer. 10,20,21 After indication, adverse event and primary suspected drug identified, we divided included cases into 3 groups: (i) the hormone therapy group, which were treated with hormone therapy agents as primary suspected drugs; (ii) the taxane group, a positive control group which were treated with taxanes as primary suspected drugs; and (iii) the other primary suspected drug group, a negative control group, which were treated with other primary suspected drugs. We further excluded cases aged <18 years, cases with ILD complications before medication, cases in the hormone therapy with taxanes combination, cases in the taxane group with hormone therapy combination, or hormone combination therapy cases without the defined combination above.…”

Section: With Prostate Cancer Indication In the Indi Table According Tomentioning

confidence: 99%

Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System

Shen

Yin

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aims To investigate interstitial lung disease (ILD) in men with prostate cancer receiving hormone therapy. Methods We gathered cases diagnosed with prostate cancer based on the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database from 2004 to 2020. We divided the included cases into 3 groups based on the primary suspected drugs: a hormone therapy group, a positive control group (taxanes), and a negative control group. We employed reporting odds ratio, a disproportionality method, to detect the association between ILD events and target drugs. Results We finally included a total of 85 403 cases, 69 894 cases (628 ILD event cases) in the hormone therapy group, 2302 cases (158 ILD event cases) in the positive control group and 13 207 cases (72 ILD event cases) in the negative control group. There were 394 ILD event cases (62.74%) in the hormone therapy group in Japan; 78.68% of the ILD events occurred within the first year after hormone treatment. Disproportionality analysis indicated that ILD events were significantly associated with nilutamide, flutamide, bicalutamide, goserelin, degarelix and apalutamide; the reporting odds ratios (95% confidence interval) were 32.14 (11.03–93.63), 9.93 (3.62–27.21), 8.19 (6.01–11.16), 3.74 (2.61–5.37), 2.41 (1.55–3.75) and 1.94 (1.01–3.75), respectively. Conclusion Based on this FAERS pharmacovigilance analysis, the association between ILD events and hormone therapy drugs, including bicalutamide, flutamide, nilutamide, goserelin, degarelix and apalutamide, should not be ignored, especially in the Japanese population. Lung function of prostate cancer patients should be monitored when receiving the hormone therapy drugs mentioned above, especially for the first year post medication.

show abstract

Docetaxel‐induced interstitial lung disease among patients with breast cancer: a case series and review of literature

Cited by 10 publications

References 15 publications

Docetaxel- induced organising pneumonia in a patient with advanced breast cancer: case report

Docetaxel- induced organising pneumonia in a patient with advanced breast cancer: case report

Docetaxel induced subacute interstitial lung disease in a patient with prostate cancer

Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System

Contact Info

Product

Resources

About